Siegel R, Desantis C, Jemal A
available only through 503A compounding pharmacies under physician supervision Typical research dose range / 200-800 mcg/day subcutaneously, cycled 4-8 weeks Known lethal dose (LD50) / Not established in any species studied to date Rodent acute toxicity ceiling / No mortality observed at doses exceeding 10 mg/kg intraperitoneally Most reported excess-dose symptoms / Nausea, lightheadedness, flushing, injection-site irritation Organ toxicity at supratherapeutic doses / Not demonstrated in published preclinical literature Antidote availability / No specific antidote exists
107 HsiaoAFWongMDKanouseDECollinsRLLiuHAndersenRMet alHCSUS Consortium
Reports may include testing from independent laboratories such as Janoshik, Chromate, and Freedom Diagnostics, depending on the batch
Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance
Some people take both together with breakfast for convenience, accepting a potential reduction in ALA absorption
